소아 간질의 바이오 마커로 동시 인 자기와 뇌파 감지 간기 고주파 진동

Executive Industry Relevance

Non-invasive detection and localization of high-frequency oscillations (HFOs) using simultaneous EEG and MEG offers a biomarker strategy to improve presurgical evaluation in pediatric epilepsy. This approach supports target validation by providing electrophysiological evidence of epileptogenic zones without requiring invasive intracranial recordings. Enhanced mechanistic de-risking through non-invasive HFO mapping can inform surgical planning and reduce reliance on long-term monitoring.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by localizing HFO generators concordant with interictal epileptiform discharges and seizure onset zones.
• Operational Value: Provides a reproducible method for source localization using wavelet maximum entropy on the mean (WMEM) on simultaneous EEG and MEG data.
• Predictive Value: Supports biomarker validation by demonstrating concordance between non-invasive scalp recordings and invasive intracranial EEG in pediatric patients.

Screening & Assay Development

• Assay Readiness: Facilitates preparation of validated biological systems through standardized skin preparation, electrode placement, and impedance monitoring below 10 kiloohms.
• Quantitative Outputs: Enables detection of HFOs in the ripple band (80–150 Hz) that co-occur with interictal epileptiform discharges in both EEG and MEG signals.
• Reproducibility: Supports cross-platform validation by requiring HFO events to be present in both EEG and MEG and time-locked to marked interictal discharges.

Translational & Preclinical Research

• Translational Continuity: Demonstrates how non-invasive HFO localization aligns with invasive intracranial recordings, supporting translation from discovery to preclinical validation.
• Disease-Relevant System: Applies to pediatric refractory epilepsy models where HFOs serve as biomarkers of epileptogenic tissue.
• Mechanistic De-risking: Reduces ambiguity in target identification by localizing HFO generators via inverse solutions and comparing them to clinically defined seizure onset zones.

Pipeline & Workflow Integration

The method integrates into early discovery workflows by providing electrophysiological data that inform target identification and validation prior to lead optimization.

• Discovery Biology: Supports hypothesis testing by localizing high-frequency oscillations to specific cortical regions using source imaging.
• Screening: Enables assay standardization through filtering (1 Hz high-pass, 70 Hz low-pass, 50/60 Hz notch) and artifact rejection via peripheral channel monitoring.
• Analytics: Generates source localization maps averaged over HFO event duration, visualized at 60% of maximum activation amplitude on cortical surfaces.
• Translational Research: Connects non-invasive scalp recordings to invasive validation, showing spatial concordance between HFO zones, interictal discharges, and intracranial electrode locations.
• Enterprise Reuse: Establishes a scalable protocol for multi-site studies requiring synchronized EEG-MEG acquisition and standardized source localization.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation by providing non-invasive electrophysiological correlates of epileptogenic zones.
• Operational Value: Enhances reproducibility through standardized electrode placement, impedance control, and dual-modality (EEG/MEG) signal requirements.
• Strategic Value: Improves go/no-go decisions by reducing dependence on invasive monitoring and enabling earlier target confirmation.
• Portfolio Impact: Supports risk-adjusted advancement by offering a non-invasive biomarker that aligns with surgical outcomes.

Implementation Considerations

• Requires expertise in electrophysiology, neuroimaging, and source localization techniques such as WMEM.
• Dependent on magnetoencephalography systems in magnetically shielded rooms and simultaneous EEG acquisition capabilities.
• Necessitates cross-team standardization between neurology, neurophysiology, and imaging groups for fiducial digitization and head shape modeling.
• Adaptation across model systems must account for developmental differences in head size and conductivity when applying the international 10-20 system.
• Practical limitations include the low amplitude of HFOs, susceptibility to noise, and the need for artifact rejection using peripheral channels (EOG, ECG, EMG).

Biopharma FAQs